Wed-14-02-2018, 14:37 PM
The U.S. Food and Drug Administration (FDA) has accepted Jemdel as a new drug application to treat psoriasis.
Source: valeant.com
Quote:
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for JEMDEL™1 (halobetasol propionate 0.01%) (IDP-122) lotion with a PDUFA action date of Oct. 5, 2018. If approved, JEMDEL will be the first high-potency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks. In the clinical trials, the most common adverse event was upper respiratory tract infection.
Source: valeant.com